GRPR and neoplasm: In vivo competition experiments (Table 5) using 50 μg [CuII]-BZH7 co-injected with [64/67Cu]-BZH7 resulted in a >89% reduction of tumor uptake and also a reduction of uptake in GRP-R-positive organs, e.g. >97% in pancreas, 96% in adrenals, 91% in bowel, 84% in stomach, 76% in spleen and bone.